-81.2%
PATH vs MRNA
+60.3%
-141.4%
-89.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.1% | +5.3% | -5.3% | -0.6% |
| 7D | -5.3% | +14.6% | -20.0% | -6.7% |
| 30D | -0.5% | +29.4% | -29.9% | -3.6% |
| 3M | -7.1% | +371.9% | -379.1% | -30.9% |
| 6M | +23.8% | +421.0% | -397.2% | -11.6% |
| YTD | -20.7% | +762.0% | -782.6% | -51.5% |
| 1Y | -8.1% | +944.8% | -952.8% | -46.8% |
| 3Y | -21.8% | +252.7% | -274.5% | -46.4% |
| 5Y | -76.8% | +7.3% | -84.1% | -80.0% |
| All | -81.2% | +60.3% | -141.4% | -84.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling